GB18 is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Shenzhen Kexing Pharmaceutical Co., Ltd. (1) and Kexing Biopharm Co., Ltd. (1). Registered phase: Phase 1. Conditions studied include Cancer Cachexia (CC); Cancer Cachexia; Cancer Cachexia Syndrome.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07237464 | To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants (ClinicalTrials.gov ↗) Cancer Cachexia (CC), Cancer Cachexia, Cancer Cachexia Syndrome |
Phase 1 | Recruiting |
| NCT07519564 | A Phase I Clinical Study to Evaluate the Efficacy and Safety of GB18 Injection in Patients With Tumor Cachexia (ClinicalTrials.gov ↗) Cachexia; Cancer |
Phase 1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Cancer Cachexia (CC) | 1 |
| Cancer Cachexia | 1 |
| Cancer Cachexia Syndrome | 1 |
| Cachexia; Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Shenzhen Kexing Pharmaceutical Co., Ltd. | 1 |
| Kexing Biopharm Co., Ltd. | 1 |
| Register | GB18 trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how GB18 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists GB18 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.